Lymphoma, B-Cell: Clinical Trials

3,123 trials for Lymphoma, B-Cell, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1284 completed, 493 recruiting, 405 unknown, 384 terminated. 1472 Phase 2, 1259 Phase 1, 268 Phase 3, 167 Not applicable, 80 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 21472Completed 611, Recruiting 232, Terminated 191, Unknown 181, Active not recruiting 114, Withdrawn 73, Not yet recruiting 63, Suspended 6, Enrolling by invitation 1
Phase 11259Completed 521, Recruiting 192, Terminated 177, Unknown 130, Active not recruiting 106, Withdrawn 74, Not yet recruiting 48, Suspended 8, Enrolling by invitation 3
Phase 3268Completed 112, Unknown 49, Recruiting 39, Active not recruiting 28, Terminated 26, Not yet recruiting 7, Withdrawn 5, Enrolling by invitation 1, Suspended 1
Not applicable167Completed 60, Recruiting 32, Unknown 25, Terminated 22, Not yet recruiting 10, Active not recruiting 9, Withdrawn 9
Early Phase 180Unknown 27, Recruiting 15, Completed 14, Not yet recruiting 10, Terminated 7, Suspended 3, Active not recruiting 2, Withdrawn 2
Phase 428Unknown 9, Recruiting 8, Completed 6, Not yet recruiting 3, Active not recruiting 1, Terminated 1

Follow Lymphoma, B-Cell: new trials by email Literature Review of Lymphoma, B-Cell trials Research Report on Lymphoma, B-Cell

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma
Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
Phase 2 / Phase 3RecruitingNational Cancer Institute (NCI)2712027-07-272026-11-17
Determining the Safety of CAR T-Cell Therapy for Lymphoma
Chimeric Antigen Receptor (CAR)-positive T- cells, Fludarabine, Cyclophosphamide - Lymphoma, B-Cell, Non Hodgkin Lymphoma
Phase 1Not yet recruitingUniversity of Chicago362027-07-132026-11-19
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Phase 1RecruitingNational Cancer Institute (NCI)152027-07-052026-11-05
Multi-CAR-T Cells Targeting B Cell Lymphomas
4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2 - B Cell Lymphoma (BCL)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute112027-06-012026-11-02
Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell Therapy
Prizloncabtagene Autoleucel - Large B Cell Lymphoma, LBCL
Phase 2Not yet recruitingAbelZeta Inc.552027-05-012026-10-15
Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma
golcadomide, Obinutuzumab, Polatuzumab - Multi Center, Phase 2
Phase 2Not yet recruitingM.D. Anderson Cancer Center602027-04-292026-11-05
Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma
Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma
Phase 1RecruitingCity of Hope Medical Center162027-04-172026-11-13
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Molecular and Cellular Characterization of MALT Lymphoma
MALT Lymphoma
Not yet recruitingInternational Extranodal Lymphoma Study Group (IELSG)4002027-04-012026-11-12
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1RecruitingSunil G. Iyer452027-03-312026-11-13
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Biospecimen Collection, Computed Tomography, Positron Emission Tomography - Recurrent Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma
Phase 1RecruitingNational Cancer Institute (NCI)302027-03-262026-10-20
Microbiome Intervention for CAR-T Optimization and Response (MICRO-CART)
Live Biotherapeutic Product (LBP), Placebo - Lymphoma, B-Cell, Multiple Myeloma
Phase 1Not yet recruitingUniversity of Chicago322027-02-232026-10-22
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Infusion of Axicabtagene Ciloleucel - Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2RecruitingZhujiang Hospital152027-02-012025-03-30
Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia
Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL
Phase 1Not yet recruitingMedical University of South Carolina182027-02-012026-11-13
Study to Evaluate the Feasibility and Safety of Autologous Cytokine-Induced Killer Cells (CIK_D332) in Combination With Tafasitamab and Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The treatment regimen consists of a combination of Tafasitamab, Lenalidomide, and CIK_D332 - Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 1Not yet recruitingIstituto Oncologico Veneto IRCCS142027-01-312026-11-03
Autologous iC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma
Autologous C7R.CD30-CAR-EBVSTs - Diffuse Large B-Cell Lymphoma (DLBCL), Hodgkin Lymphoma
Phase 1Not yet recruitingThe Methodist Hospital Research Institute212027-01-152026-11-12
Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene
Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)502027-01-112026-10-14
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL)
Phase 1 / Phase 2Not yet recruitingVitruviae1082027-01-012026-08-06
Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome
Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia
Phase 2Not yet recruitingFred Hutchinson Cancer Center522027-01-012026-09-14
Axatilimab + CAR-T for High-Risk Lymphoma
Axatilimab - Diffuse Large B Cell Lymphoma (DLBCL), Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Phase 1Not yet recruitingNorthside Hospital, Inc.292026-12-312026-10-16

Showing 20 of 3123. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (1833)  ·  Lymphoma, Follicular (985)  ·  Burkitt Lymphoma (978)  ·  Lymphoma, Non-Hodgkin (928)  ·  Lymphoma (892)  ·  Lymphoma, B-Cell, Marginal Zone (867)  ·  Lymphoma, Mantle-Cell (834)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (797)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (675)  ·  Lymphoma, Large-Cell, Immunoblastic (490)  ·  Hodgkin Disease (456)  ·  Recurrence (410)  ·  Waldenstrom Macroglobulinemia (370)  ·  Leukemia (355)

Broader conditions

Hemic and Lymphatic Diseases (3123)  ·  Neoplasms by Histologic Type (3108)  ·  Immune System Diseases (3103)  ·  Immunoproliferative Disorders (3098)  ·  Lymphatic Diseases (3096)  ·  Lymphoproliferative Disorders (3057)  ·  Neoplasms (2976)  ·  Lymphoma (2231)  ·  Lymphoma, Non-Hodgkin (2195)  ·  Hematologic Diseases (1242)  ·  Pathological Conditions, Signs and Symptoms (1147)  ·  Pathologic Processes (1139)  ·  Disease Attributes (1100)  ·  Leukemia, Lymphoid (1077)

Interventions

Rituximab (650)  ·  Cyclophosphamide (565)  ·  Vincristine (275)  ·  Prednisone (254)  ·  Doxorubicin (244)  ·  Etoposide (217)  ·  Cytarabine (152)  ·  Lenalidomide (149)  ·  fludarabine phosphate (146)  ·  Filgrastim (144)  ·  fludarabine (137)  ·  Peripheral Blood Stem Cell Transplantation (133)  ·  Methotrexate (119)  ·  Dexamethasone (110)  ·  Radiotherapy (110)

Sponsors

National Cancer Institute (NCI) (196)  ·  Fred Hutchinson Cancer Center (85)  ·  M.D. Anderson Cancer Center (82)  ·  Memorial Sloan Kettering Cancer Center (65)  ·  City of Hope Medical Center (51)  ·  Ruijin Hospital (46)  ·  Mayo Clinic (38)  ·  Novartis Pharmaceuticals (35)  ·  Masonic Cancer Center, University of Minnesota (32)  ·  Hoffmann-La Roche (30)  ·  Case Comprehensive Cancer Center (28)  ·  The First Affiliated Hospital of Soochow University (27)  ·  Children's Oncology Group (26)  ·  Fondazione Italiana Linfomi - ETS (23)  ·  Jonsson Comprehensive Cancer Center (23)

Countries

United States (1765)  ·  China (638)  ·  France (287)  ·  Italy (246)  ·  United Kingdom (209)  ·  Spain (199)  ·  Germany (180)  ·  Canada (179)  ·  Australia (167)  ·  South Korea (148)  ·  Belgium (121)  ·  Poland (102)  ·  Japan (87)  ·  Switzerland (87)  ·  Israel (83)

Top investigators

Ajay Gopal (13)  ·  Brenda Sandmaier (9)  ·  Craig Moskowitz, MD (7)  ·  Elias Jabbour (7)

Results publications

PMID 34515338, PMID 41671463, PMID 35622074, PMID 32499241, PMID 40550489, PMID 26373676, PMID 39319495, PMID 27282998, PMID 34398557, PMID 40802906, PMID 34780125, PMID 39813680, PMID 20660832, PMID 23753028, PMID 30125215, PMID 30770362, PMID 32589970, PMID 34310745, PMID 34687939, PMID 37486616, PMID 38551807, PMID 39563886, PMID 40195173, PMID 42699559, PMID 11807147, PMID 16449523, PMID 16648042, PMID 16754935, PMID 17242396, PMID 19949018, PMID 20028764, PMID 20548096, PMID 21482186, PMID 21527516, PMID 22002018, PMID 22337718, PMID 23065509, PMID 23233721, PMID 23834234, PMID 24224624, PMID 24862638, PMID 25317870, PMID 25381051, PMID 26193343, PMID 26248505, PMID 26755709, PMID 27209293, PMID 27482888, PMID 27879257, PMID 28054442

NIH funding

P30CA033572 (41), 2023 (37), P30CA015704 (36), U10CA032102 (23), P30CA015083 (22), P30CA043703 (22), 2017 (21), 2016 (20), 2015 (19), P30CA006973 (17), 2018 (15), P30CA016672 (15), 2025 (13), P30CA022453 (13), P30CA036727 (12)